文献速递肾移植

二甲双胍使用与肾移植受者长期临床结局

Metformin Use and Long-term Clinical Outcomes in Kidney Transplant Recipients.
PubMed 文献 · Am J Kidney Dis · 2023-03-23

该回顾性队列研究纳入韩国6家三级转诊中心的1995例合并糖尿病的肾移植受者,其中1193例使用二甲双胍超过90天,802例未使用。二甲双胍使用与死亡删失移植物失败风险降低相关(AHR 0.47,95%CI 0.23-0.96,P=0.038),与全因死亡和活检证实的急性排斥无显著关联,未确认二甲双胍相关乳酸酸中毒病例。

要点

  • 二甲双胍使用与死亡删失移植物失败风险降低相关(AHR 0.47,95%CI 0.23-0.96,P=0.038)。
  • 二甲双胍使用与全因死亡(AHR 0.94,95%CI 0.32-2.76,P=0.915)和活检证实的急性排斥(AHR 0.98,95%CI 0.62-1.54,P=0.942)无显著关联。
  • 本队列中未确认二甲双胍相关乳酸酸中毒病例,较高剂量与较低的死亡删失移植物失败和活检证实的急性排斥风险相关。

核心结论

  • 二甲双胍使用可能使肾移植受者获益,表现为与死亡删失移植物失败风险降低相关且无二甲双胍相关乳酸酸中毒事件。
  • 需要随机对照试验验证这些观察性发现。

研究设计与样本

  • 回顾性队列研究,纳入韩国6家三级转诊中心的1995例合并糖尿病的肾移植受者。
  • 二甲双胍使用定义为肾移植后使用二甲双胍超过90天;1193例为二甲双胍使用者,802例未使用二甲双胍。
  • 采用多因素Cox回归进行生存分析,使用Fine和Gray模型进行竞争风险分析,并以时变协变量建模二甲双胍使用变化。
  • 在landmark分析中考虑二甲双胍使用、平均每日剂量和血红蛋白A1c变化以处理时变混杂。

主要发现

  • 二甲双胍使用与死亡删失移植物失败风险降低相关(AHR 0.47,95%CI 0.23-0.96,P=0.038)。
  • 二甲双胍使用与全因死亡无显著关联(AHR 0.94,95%CI 0.32-2.76,P=0.915)。
  • 二甲双胍使用与活检证实的急性排斥无显著关联(AHR 0.98,95%CI 0.62-1.54,P=0.942)。
  • 亚组分析中,二甲双胍使用与移植前糖尿病和移植后糖尿病两组全因死亡风险降低及死亡删失移植物失败风险降低相关。
  • 二甲双胍使用与移植后糖尿病组活检证实的急性排斥风险降低相关,但在移植前糖尿病组效果较差;本队列中未确认二甲双胍相关乳酸酸中毒病例;较高剂量二甲双胍与较低的死亡删失移植物失败和活检证实的急性排斥风险相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 关于新型降糖药物如SGLT2抑制剂的数据有限。
  • 可能对其他人群的普遍适用性有限。
  • 需要随机对照试验验证这些观察性发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Metformin has been recommended for some patients with advanced chronic kidney disease. However, the value of metformin in kidney transplant recipients (KTRs) with pretransplant diabetes mellitus (DM) or posttransplant DM is uncertain. We investigated the clinical effects of metformin in KTRs. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: A total of 1,995 KTRs with diabetes from 6 tertiary referral centers in the Republic of Korea. EXPOSURE: Metformin usage was defined as the use of metformin for>90 days after kidney transplantation; 1,193 KTRs were metformin users, and 802 KTRs did not use metformin. Changing usage of metformin among those exposed for >90 days was also characterized. OUTCOME: Primary outcomes were all-cause mortality and death-censored graft failure (DCGF). Secondary outcomes were biopsy-proven acute rejection (BPAR) and lactic acidosis events. ANALYTICAL APPROACH: Survival analyses were conducted using multivariable Cox regression and competing risk analyses using Fine and Gray models. Changes in metformin use over time were modeled using a time-varying covariate. Metformin usage, mean daily dose, and hemoglobin A1c (HbA1c) changes were considered in the landmark analysis to address time-varying confounding. RESULTS: Metformin use was associated with a lower risk of DCGF (adjusted hazard ratio [AHR], 0.47 [95% CI, 0.23-0.96], P=0.038); there was no significant association with all-cause mortality (AHR, 0.94 [95% CI, 0.32-2.76], P=0.915) or BPAR (AHR 0.98 [95% CI, 0.62-1.54], P=0.942). In the subgroup analysis, metformin usage was associated with a reduced risk of all-cause mortality and a lower risk of DCGF for both pretransplantation DM and posttransplant DM groups. Metformin usage was associated with a lower risk of BPAR in the posttransplant DM group, although it was less effective in the pretransplantation DM group. There was no confirmed case of metformin-associated lactic acidosis (MALA) in the present cohort. A higher dose of metformin was correlated with lower risks of DCGF and BPAR. LIMITATIONS: Data on newer antidiabetic drugs such as SGLT2 inhibitors are limited, and there is potential limited generalizability to other populations. CONCLUSIONS: Metformin usage may benefit KTRs, as evidenced by its association with a reduced risk of DCGF and the absence of MALA events. Randomized controlled trials are needed to validate these observational findings.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Kwon S, Kim YC, Kwon H, et al. Metformin Use and Long-term Clinical Outcomes in Kidney Transplant Recipients. Am J Kidney Dis. 2023. PMID: 36965829. doi:10.1053/j.ajkd.2023.01.446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。